Sara J Adair

List of Publications by Year
in descending order

17	802	949033 11	1051228 16
papers	citations	h-index	g-index

17	17	17	1682
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. Developmental Cell, 2022, 57, 1331-1346.e9.	3.1	9
2	Apoptotic Bodies in the Pancreatic Tumor Cell Culture Media Enable Labelâ€Free Drug Sensitivity Assessment by Impedance Cytometry. Advanced Biology, 2021, 5, 2100438.	1.4	14
3	Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28068-28079.	3.3	48
4	Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth. Cell Reports, 2019, 28, 1845-1859.e5.	2.9	93
5	CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clinical Cancer Research, 2018, 24, 1415-1425.	3.2	73
6	CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nature Communications, 2018, 9, 4275.	5.8	56
7	Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget, 2018, 9, 8972-8984.	0.8	3
8	Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Annals of Surgical Oncology, 2016, 23, 1993-2000.	0.7	7
9	A Thirteen-Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of Interest. PLoS ONE, 2014, 9, e105631.	1.1	31
10	Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer. Neoplasia, 2014, 16, 562-571.	2.3	30
11	Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib. Neoplasia, 2013, 15, 143-IN10.	2.3	86
12	Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens. PLoS ONE, 2013, 8, e77065.	1.1	62
13	Effect of trametinib in combination with panitumumab and trastuzumab on tumor growth in an orthotopic xenograft model of human pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, 190-190.	0.8	2
14	Targeting occult metastatic disease: A hematogenously derived xenograft model of human pancreatic tumor growth in the murine liver.. Journal of Clinical Oncology, 2013, 31, 198-198.	0.8	0
15	Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment. Molecular Cancer Therapeutics, 2011, 10, 2135-2145.	1.9	185
16	Treatment of ovarian cancer cell lines with 5-aza-2â€²-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunology, Immunotherapy, 2009, 58, 589-601.	2.0	91
17	The TAG Family of Cancer/Testis Antigens is Widely Expressed in a Variety of Malignancies and Gives Rise to HLA-A2â€“Restricted Epitopes. Journal of Immunotherapy, 2008, 31, 7-17.	1.2	12